GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (FRA:8NE) » Definitions » Cyclically Adjusted PB Ratio

Lisata Therapeutics (FRA:8NE) Cyclically Adjusted PB Ratio : 0.04 (As of Jun. 06, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lisata Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Lisata Therapeutics's current share price is €2.76. Lisata Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €72.01. Lisata Therapeutics's Cyclically Adjusted PB Ratio for today is 0.04.

The historical rank and industry rank for Lisata Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:8NE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.07   Max: 1.93
Current: 0.04

During the past years, Lisata Therapeutics's highest Cyclically Adjusted PB Ratio was 1.93. The lowest was 0.01. And the median was 0.07.

FRA:8NE's Cyclically Adjusted PB Ratio is ranked better than
94.1% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs FRA:8NE: 0.04

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Lisata Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €4.762. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €72.01 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Lisata Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Lisata Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Cyclically Adjusted PB Ratio Chart

Lisata Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.08 0.07 0.02 0.03

Lisata Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.02 0.03 0.04

Competitive Comparison of Lisata Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Lisata Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lisata Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Cyclically Adjusted PB Ratio falls into.



Lisata Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Lisata Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.76/72.01
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Lisata Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.762/131.7762*131.7762
=4.762

Current CPI (Mar. 2024) = 131.7762.

Lisata Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 246.585 100.560 323.132
201409 206.662 100.428 271.171
201412 193.524 99.070 257.413
201503 177.198 99.621 234.393
201506 159.988 100.684 209.394
201509 133.486 100.392 175.217
201512 57.556 99.792 76.003
201603 31.124 100.470 40.822
201606 13.629 101.688 17.662
201609 17.554 101.861 22.709
201612 8.475 101.863 10.964
201703 -1.240 102.862 -1.589
201706 81.517 103.349 103.939
201709 71.198 104.136 90.096
201712 67.501 104.011 85.520
201803 57.922 105.290 72.493
201806 57.754 106.317 71.584
201809 53.659 106.507 66.390
201812 50.418 105.998 62.679
201903 44.356 107.251 54.499
201906 38.146 108.070 46.514
201909 33.030 108.329 40.179
201912 26.690 108.420 32.440
202003 22.002 108.902 26.624
202006 28.897 108.767 35.010
202009 24.779 109.815 29.734
202012 20.677 109.897 24.794
202103 23.351 111.754 27.535
202106 21.950 114.631 25.233
202109 21.044 115.734 23.961
202112 20.483 117.630 22.946
202203 19.911 121.301 21.630
202206 19.298 125.017 20.341
202209 9.252 125.227 9.736
202212 7.956 125.222 8.372
202303 7.118 127.348 7.366
202306 6.579 128.729 6.735
202309 6.096 129.860 6.186
202312 5.417 129.419 5.516
202403 4.762 131.776 4.762

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lisata Therapeutics  (FRA:8NE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Lisata Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lisata Therapeutics (FRA:8NE) Business Description

Traded in Other Exchanges
Address
110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Lisata Therapeutics (FRA:8NE) Headlines

No Headlines